Form 4: ORIC CMO Pratik Multani Awarded Equity Compensation

Oric Pharmaceuticals' Chief Medical Officer, Pratik S. Multani, was granted 214,000 stock options and 35,500 restricted stock units on January 2, 2026.

Summary

• Pratik S. Multani, Chief Medical Officer of Oric Pharmaceuticals, Inc. (ORIC), was the reporting person.
• Acquired 214,000 stock options with an exercise price of $8.17 per share.
• Acquired 35,500 Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Common Stock.
• The transaction date for both the stock options and RSUs was January 2, 2026.
• The stock options begin vesting on January 2, 2027, with 25% vesting then, and 1/36th of the remaining shares vesting each month thereafter.
• The RSUs vest in three equal installments on December 15, 2026, December 15, 2027, and December 15, 2028.
• The stock options have an expiration date of January 1, 2036.

Sentiment

Score: 7

Explanation: The grant of significant equity awards to a key executive like the Chief Medical Officer is generally viewed positively as it aligns management's long-term interests with those of shareholders, incentivizing performance and retention. It is a routine compensation event, not indicative of immediate operational changes.

Positives

• Chief Medical Officer Pratik S. Multani was granted significant equity awards (214,000 stock options and 35,500 restricted stock units), which aligns management incentives with long-term shareholder interests.
• The multi-year vesting schedules for both options and RSUs promote executive retention and sustained focus on company performance.

Future Outlook

The equity awards are structured with multi-year vesting schedules, indicating a long-term incentive for the Chief Medical Officer to contribute to the company's future performance and strategic objectives.

Industry Context

Equity grants, including stock options and restricted stock units, are a common form of executive compensation in the biotechnology and pharmaceutical industries, designed to attract, retain, and incentivize key talent by aligning their interests with long-term shareholder value creation.

Comparison to Industry Standards

• The grant of stock options and restricted stock units to a Chief Medical Officer is a standard compensation practice within the biotechnology sector, comparable to similar incentive structures observed at peer companies for their executive teams, aiming to foster long-term commitment and performance.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through incentivized and aligned management.
• Employees: May signal stability and commitment from leadership, potentially boosting morale and confidence in the company's direction.

Next Steps

• Shares subject to the stock option will begin vesting on January 2, 2027, with 25% vesting then, and the remainder vesting monthly thereafter.
• Restricted Stock Units will vest in three equal installments on December 15, 2026, December 15, 2027, and December 15, 2028.

Key Dates

Recommendation

This Form 4 reports a routine equity compensation grant to a key executive, which is a standard practice for aligning management incentives with shareholder interests. It does not provide new fundamental information that would typically warrant a change in an investment thesis or a strong buy/sell recommendation based solely on this filing.

Keywords

Oric Pharmaceuticals, ORIC, Form 4, Insider Transaction, Stock Option, Restricted Stock Unit, Equity Grant, Executive Compensation, Pratik S. Multani